ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Ankylosing spondylitis (AS)"

  • Abstract Number: 0546 • ACR Convergence 2024

    Hiding in Plain Sight: The Impact of Implementing an Automated Inflammatory Back Pain Screening Tool on the Identification of Axial Spondyloarthritis in a Community Rheumatology Practice

    Nehad Soloman1, Jawad Bilal2 and John Tesser3, 1Arizona Arthritis & Rheumatology Associates, P.C., Glendale, AZ, 2Arizona Arthritis & Rheumatology Associates, PC, Tucson, AZ, 3Arizona Arthritis and Rheumatology Associates, P.C., Phoenix, AZ

    Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic inflammatory disease affecting 1.4% of the US adult population.  The leading clinical symptom of axSpA is chronic inflammatory…
  • Abstract Number: 0603 • ACR Convergence 2024

    Superior Effectiveness and Comparable Drug Retention of Anti-TNF Therapy versus Anti-IL-17A in Ankylosing Spondylitis After First Anti-TNF Failure: A Propensity Score-Matched Analysis from the Czech ATTRA Registry

    Jakub Závada1, Jana Baranová2, Karel Pavelka1, Jiří Vencovský3, Pavel Horak4, Kateřina Kusalová2 and Ladislav Šenolt3, and collaborators of the ATTRA registry, 1Institute of Rheumatology and Charles University, Praha, Czech Republic, 2Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic, 3Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, 43rd Department of Internal Medicine - Nephrology, Rheumatology and Endocrinology, University Hospital Olomouc & Palacky University Olomouc, Faculty of Medicine and Dentistry, Olomouc, Olomoucky kraj, Czech Republic

    Background/Purpose: This study aims to compare the drug survival, effectiveness, and safety of anti-IL-17A and anti-TNF drugs in patients with Ankylosing Spondylitis (AS) following the…
  • Abstract Number: 1437 • ACR Convergence 2024

    Impact of Early Diagnosis in Patients with Axial Spondyloarthritis on Arterial Stiffness Progression

    Sze-Lok Lau1, Huan Meng2, Isaac Cheng1, Bryan PY Yan1, Alex PW Lee1, Ho So1 and Lai-shan Tam3, 1The Chinese University of Hong Kong, Hong Kong, Hong Kong, 2The Faculty of Medicine, CUHK, Hong Kong, China (People's Republic), 3The Chinese University of Hong Kong, New Territories, Hong Kong

    Background/Purpose: In patients with axial spondyloarthritis (AxSpA), we have reported that higher inflammatory burden as reflected by a longer disease duration, delay in diagnosis and…
  • Abstract Number: 1759 • ACR Convergence 2024

    Predictors of Radiographic Spinal Progression in Patients with Axial Spondyloarthritis Receiving IL-17A Inhibitor or TNF Inhibitor Therapy over 2 Years: A Post Hoc Analysis of a Phase IIIb Study

    Denis Poddubnyy1, Juergen Braun2, Pedro M Machado3, Victoria Navarro Compán4, Lianne S Gensler5, Kay Geert Hermann6, Erhard Quebe-Fehling7, Christelle C Pieterse8, Aimee Readie9, Corine Gaillez7 and Xenofon Baraliakos10, 1Charite-Universitatsmedizin Berlin, Berlin, Germany, 2Rheuma Praxis, Ruhr-University Bochum, Berlin, Germany, 3Department of Neuromuscular Diseases and Centre for Rheumatology, University College London, London, United Kingdom, 4La Paz University Hospital, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain, 5Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, 6Charite Medical School, Berlin, Germany, 7Novartis Pharma AG, Basel, Switzerland, 8Syneos Health, Amsterdam, Netherlands, 9Novartis Pharmaceuticals Corporation, East Hanover, NJ, 10Rheumazentrum Ruhrgebiet Herne, and Ruhr-University Bochum, Bochum, Germany

    Background/Purpose: Previous studies have identified predictors of radiographic spinal progression in patients with axial spondyloarthritis (axSpA). In this post hoc analysis of the SURPASS study…
  • Abstract Number: 2367 • ACR Convergence 2024

    Updated Long-Term Safety and Tolerability of Bimekizumab in Patients with Axial Spondyloarthritis and Psoriatic Arthritis: Pooled Results from Phase 2b/3 Studies

    Philip Mease1, Denis Poddubnyy2, Rajan Bajracharya3, Barbara Ink3, Alexander Marten4, Ute Massow4, Vishvesh Shende3, Myriam Manente5, Luke Peterson6, Katy White3, Peter Nash7 and Lianne S Gensler8, 1Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, 2Charite-Universitatsmedizin Berlin, Berlin, Germany, 3UCB Pharma, Slough, United Kingdom, 4UCB Pharma, Monheim am Rhein, Germany, 5UCB Pharma, Braine-l'Alleud, Belgium, 6UCB Pharma, Morrisville, NC, 7School of Medicine, Griffith University, Sunshine Coast, Queensland, Australia, 8Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA

    Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)‑17F in addition to IL‑17A. BKZ was generally well tolerated by patients (pts)…
  • Abstract Number: 0550 • ACR Convergence 2024

    Is the Diagnostic Delay Getting Shorter with Time for Patients with Spondyloarthritis? Data from the International ASAS-PerSpA Study

    Nelly Ziade1, Ihsane Hmamouchi2, Clementina López Medina3, Maroun Aoun4, Sherif Gamal5, Maxime Dougados6 and Bassel Elzorkany7, and ASAS-PerSpA, 1Saint-Joseph University, Beirut, Lebanon, 2International University of Rabat, Rabat, Morocco, 3Reina Sofia University Hospital, Cordoba, Spain, 4Saint Joseph University, Beirut, Lebanon, 5Cairo University, Cairo, Egypt, 6Rheumatology Department, Cochin Hospital and Clinical Epidemiology and Biostatistics, University of Paris, INSERM (U1153), Paris, France, 7Private (BZRC), Cairo, Egypt

    Background/Purpose: Although diagnostic tools and management of spondyloarthritis (SpA) have recently improved, data on their impact on diagnostic delay (DD) are still conflicting. In this…
  • Abstract Number: 0819 • ACR Convergence 2024

    The Assessment of SpondyloArthritis International Society (ASAS) Definition of Difficult-to-Manage Axial Spondyloarthritis

    Denis Poddubnyy1, Xenofon Baraliakos2, Victoria Navarro Compán3, Murat Torgutalp4 and Desiree van der Heijde5, and ASAS Difficult-to-Manage Axial Spondyloarthritis Task Force, 1Charite-Universitatsmedizin Berlin, Berlin, Germany, 2Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, 3La Paz University Hospital, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain, 4Charite Universitatsmedizin - Berlin, Berlin, Germany, 5Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands

    Background/Purpose: Non-response to standard treatments represents a management challenge in axial Spondyloarthritis (axSpA). The Assessment of SpondyloArthritis international Society (ASAS) seeks to define 'difficult-to-manage axSpA'…
  • Abstract Number: 1440 • ACR Convergence 2024

    Significant Indicators Identified for Carotid Doppler Ultrasound Use in Axial Spondyloarthritis Patients Without Conventional Cardiovascular Risk Factors

    Brona Dinneen1 and Finbar O'Shea2, 1St James's Hospital,, Dublin, Dublin, Ireland, 2St James's Hospital, Dublin, Dublin, Ireland

    Background/Purpose: The EULAR  cardiovascular screening recommendations advocate for the use of carotid dopplers in patients with inflammatory joint diseases to detect subclinical atherosclerosis. Despite these…
  • Abstract Number: 1760 • ACR Convergence 2024

    A Phase 2 Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of a Mitogen-activated Protein Kinase-Activated Protein Kinase 2 (MK2) Inhibitor in Active Ankylosing Spondylitis

    Walter Maksymowych1, Robert Lambert1, Paula Śliwinska-Stańczyk2, Piotr Adrian Klimiuk3, Anusha Yeshokumar4, Elizabeth Cerullo4, Rebecca Kepich4, Chahin Pachai4 and Steven Greenberg4, 1University of Alberta, Edmonton, AB, Canada, 2Centrum Medyczne ReumaPark, Warsaw, Poland, 3Medical University of Bialystok and Inter Clinic Piotr Adrian Klimiuk, Department of Rheumatology and Internal Diseases, Białystok, Poland, 4Bristol Myers Squibb, Princeton, NJ

    Background/Purpose: CC-99677 (also known as BMS-986371) is a novel, orally bioavailable, small-molecule covalent inhibitor of mitogen-activated protein (MAP) kinase-activated protein kinase 2 (MK2). The MK2…
  • Abstract Number: 0553 • ACR Convergence 2024

    Analyzing the Utilization of HLA-B27 Testing in a Large Rural Health System: Implications for Diagnostic Appropriateness

    Sanjeev Shrestha1, Angela Bobak2, Idorenyin Udoeyo3, Pradeep Puri4, Jordan Law5 and David Bulbin6, 1Geisinger Medical Center, Bloomsburg, PA, 2Geisinger Medical Center Internal Medicine Residency, Danville, PA, 3Geisinger Medical Center, Danville, PA, 4Geisinger Medical Center, Danville, 5Geisinger Health System, Danville, 6Geisinger Health System, Danville, PA

    Background/Purpose: Human leukocyte antigen (HLA)-B27 is linked to spondyloarthropathies (SpA), uveitis, and inflammatory bowel disease (IBD). By analyzing ordering diagnoses and final diagnoses during patient…
  • Abstract Number: 0820 • ACR Convergence 2024

    The Classification in Axial Spondyloarthritis Inception Cohort Study: Performance of the 2009 Assessments in Spondyloarthritis International Society Classification Criteria

    Walter Maksymowych1, Desiree van der Heijde2, Liron Caplan3, Robert Landewé4, Lianne S Gensler5, Pedro M. Machado6, Alexandre Sepriano7, Floris van Gaalen8, Miranda van Lunteren9, Ben Vandermeer10, Joachim Sieper11, Atul Deodhar12 and Martin Rudwaleit13, and on behalf of CLASSIC Study investigators, 1University of Alberta, Edmonton, AB, Canada, 2Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, 3Rocky Mountain Regional VAMC, Aurora, CO, 4Amsterdam University Medical Center, Meerssen, Netherlands, 5Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, 6Department of Rheumatology, University College London Hospitals NHS Foundation Trust; and Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS Trust; and Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, 7Leiden University Medical Centre, Portela Loures, Portugal, 8LUMC, Leiden, Zuid-Holland, Netherlands, 9Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands, 10University of Alberta, Edmonton, Canada, 11Charité University Medicine Berlin, Berlin, Germany, 12Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, 13University of Bielefeld, Klinikum Bielefeld, Bielefeld, Germany

    Background/Purpose: The 2009 ASAS classification criteria had sensitivity of 83% and specificity of 84% for a rheumatologist diagnosis of axSpA. However, their implementation revealed varying…
  • Abstract Number: 1445 • ACR Convergence 2024

    Systematic Characterization of MRI Lesions Per ASAS Definitions in the Sacroiliac Joints of Patients with Axial Spondyloarthritis and Comparisons Among Subgroups with Psoriasis, Iritis, Colitis, AxSpA Alone, and Matched Back Pain Controls

    Ulrich Weber1, Susanne Pedersen2, Ozun Bayindir Tsechelidis3, Robert Lambert4, Joel Paschke5, Stephanie Wichuk4 and Walter Maksymowych4, 1Practice Buchsbaum Schaffhausen, Schaffhausen, Switzerland, 2Rigshospitalet, København, Denmark, 3Ottawa University, Ottawa, ON, Canada, 4University of Alberta, Edmonton, AB, Canada, 5CARE Arthritis, Edmonton, AB, Canada

    Background/Purpose: There is limited information on the frequency and topographical distribution of MRI lesions in the sacroiliac joints (SIJ) of patients with axSpA according to…
  • Abstract Number: 1837 • ACR Convergence 2024

    Baseline Multiome Sequencing of CD45RO+CD45RA-CD4+ T Cell Reveals Distinct Immune Profiles Associated with Subsequent Response to Secukinumab Treatment

    Addison Pacheco1, Zoya Qaiyum2, Fataneh Tavasolian3, Melissa Lim4, Michael Tang1 and Robert Inman1, 1University Health Network, Toronto, ON, Canada, 2Krembil Research Institute, Toronto, ON, Canada, 3Krembil Research Institute - the University Health Network, Toronto, ON, Canada, 4University of Toronto, Toronto, ON, Canada

    Background/Purpose: Our study aims to discriminate immune profiles between secukinumab responders (SEC-R) and nonresponders (SEC-NR) in axial spondyloarthritis (axSpA) patients before biologic treatment.Methods: CD45RO+CD45RA-CD4+ T…
  • Abstract Number: 0554 • ACR Convergence 2024

    Different Prevalence of Intestinal Inflammation in Radiographic and Non-radiographic Axial Spondyloarthritis. Data from EISER Study

    Carolina Merino1, Zulema Plaza2, Jordi Gratacos Masmitja3, Iago Rodríguez-Lago4, Elisa Trujillo5, Ignacio Marin-Jimenez6, Eva Perez Pampin7, Manuel Barreiro8, Vanesa Hernández-Hernández9, Marta Carrillo-Palau10, Maria Luz Garcia Vivar11, Maria Carmen Muñoz12, María Lourdes Ladehesa-Pineda13, Eva Iglesias Flores14, Yago González-Lama15, Marta Arevalo Salaet16, Xabier Calvet17, Ana Gutierrez-Casbas18 and JESUS SANZ SANZ19, and EISER group, 1Hospital Universitario Puerta de Hierro Majadahonda., Majadahonda (Madrid), Spain, 2Fundacion Española de Reumatología, Madrid, Spain, 3University Hospital Parc Taulí, Sabadell, Spain, 4Gastroenterology department. Hospital Universitario Galdakao-Usansolo, Instituto de Investigación Sanitaria Biobizkaia, Galdakao, Bizkaia, Spain, Galdakao, Spain, 5Rheumatology department. Hospital Universitario de Canarias, La Laguna. Tenerife, Spain, 6Gastroenterology department. Hospital Universitario Gregorio Marañón, Madrid, Spain, 7Rheumatology department. Instituto de Investigación Sanitaria de Santiago (IDIS), Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Santiago de Compostela, Spain, 8Gastroenterology department. Hospital Clínico Universitario de Santiago de Compostela Santiago de Compostela, Spain, Santiago de Compostela, Spain, 9Hospital Universitario de Canarias, San Cristobal de La Laguna, Canarias, Spain, 10Gastroenterology department. Hospital Universitario Canarias, La Laguna, Spain., Santa Cruz de Tenerife, Spain, 11Basurto Hospital, Bilbao, Spain, 12Gastroenterology department. Hospital Universitario Basurto Hospital Universitario Basurto. Bilbao. Spain., Bilbao., Spain, 13IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Andalucia, Spain, 14Gastroenterology department. Hospital Reina Sofia, Córdoba, Spain, Cordoba, Spain, 15Servicio de Gastroenterología, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA , Madrid, Majadahonda, Spain, 16Parc Tauli Hospital Universitari I3PT, Rheumatology, Medicine Department, UAB, Sabadell, Spain, 17Gastroenterology department. Parc Taulí, Hospital Universitari. Institut d’Investigació i Innovació Parc Taulí. Universitat Autònoma de Barcelona. Sabadell, Spain, Sabadell, Spain, 18Gastroenterology department. Hospital General Universitario de Dr. Balmis de Alicante. ISABIAL y CIBERehd, Alicante, Spain, Alicante, Spain, 19Hospital Universitario Puerta de Hierro Majadahonda., Majadahonda, Spain

    Background/Purpose: Axial spondyloarthritis (AxSpA) encompasses both non-radiographic axial spondyloarthritis (nr-AxSpA) and radiographic axial spondyloarthritis (r-AxSpA), also known as ankylosing spondylitis (AS). Although nr-AxSpA is often…
  • Abstract Number: 0821 • ACR Convergence 2024

    Validation of ASAS Preliminary Data-Driven MRI Lesion Cut-offs for a Positive MRI of the Sacroiliac Joints in Patients with Axial Spondyloarthritis and Subgroups with Psoriasis, Iritis, and Colitis

    Susanne Pedersen1, Ulrich Weber2, Ozun Bayindir Tsechelidis3, Robert Lambert4, Joel Paschke5, Stephanie Wichuk4 and Walter Maksymowych4, 1Rigshospitalet, København, Denmark, 2Practice Buchsbaum Schaffhausen, Schaffhausen, Switzerland, 3Ottawa University, Ottawa, ON, Canada, 4University of Alberta, Edmonton, AB, Canada, 5CARE Arthritis, Edmonton, AB, Canada

    Background/Purpose: Recent analysis of MRI scans from the 2009 ASAS classification cohort has led to a new proposal for the application of more stringent MRI…
  • 1
  • 2
  • 3
  • …
  • 62
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology